Peter Umukoro is a Nephrology physician. OpenAlex indexes 32 publications with 253 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Hospital Ln Ste 145
Danville, IN 461222000
Telephone
317-718-2460Provider last certified this registry record 4 Dec 2024.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202510 payments
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- Amgen Inc.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62%Angiotensin receptor blocker (ARB)12.6%Losartan Potassium92%Valsartan9%Part D<11 patientsLoop diuretic9.2%Torsemide69%Furosemide31%Part D≥32 patients+ 10 more classes in this area
Metabolism & gastrointestinal
17%SGLT2 inhibitor7.5%Farxiga80%Jardiance20%Part D<11 patientsVitamin D3 Analog6.3%Calcitriol100%Part D≥27 patients+ 1 more class in this area
Genitourinary & hormones
13.2%alpha-Adrenergic Blocker11.3%Tamsulosin Hcl100%Part D≥50 patients5-alpha Reductase Inhibitor1.9%Finasteride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intravenous Lidocaine Infusion for the Management of Early Postoperative Pain: A Comprehensive Review of Controlled Trials
Psychopharmacology Bulletin
2025 - Novel predictors of permanent pacemaker implantation following transcatheter aortic valve replacement
World Journal of Cardiology
2023 - Initiation of Dialysis Is Associated With Impaired Cardiovascular Functional Capacity
Journal of the American Heart Association
2022 - C-46 | Novel Predictors and Clinical Outcomes of Permanent Pacemaker Placement (PPM) Following Transcatheter Aortic Valve Replacement (TAVR): A Midwest Rural Center Experience
Journal of the Society for Cardiovascular Angiography & Interventions
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”